## **Basic Investigations**

# INDUCTION OF APOPTOSIS OF HUMAN LEUKEMIA CELLS BY $\alpha$ -ANORDRIN

Lou Liguang 楼丽广 Xu Bin 胥彬

Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 200031

The apoptosis-inducing effect of  $\alpha$ -anordrin (ANO) was investigated in this study. ANO 10-50 µM inhibited the growth of both human leukemia HL-60 and K562 cells by 19-52%. Electron microscopy showed that ANO-treated cells exhibited the drastic changes including cell shrinkage, chromatin condensation, nuclear fragmentation, typical of apoptosis. Gel electrophoresis of DNA extracted from both HL-60 and K562 cells treated with ANO revealed characteristic "ladder" pattern. ANO 50 µM for 48 h caused approximately 50-70% apoptosis. Cycloheximide (CHX) and actinomycin D (Act D) did not prevent ANO-induced apoptosis in K562 cells, however, apoptosis of HL-60 cells in the presence of ANO was partially blocked by these two agents. Moreover, it was found that tamoxifen synergically potentiated and estradiol partially antagonized ANOinduced apoptosis in HL-60 cells. Results demonstrated that ANO could induce tumor cell apoptosis, which might contribute to its anticancer action.

Key words: Apoptosis, a-anordrin, Leukemia cells.

Anordrin is a contraceptive agent which was first developed in China. Previous study showed that  $\alpha$  isomer of anordrin (ANO) exhibited antitumor effect both *in vitro* and *in vivo*.<sup>1,2</sup> It was also found that at small doses, ANO could induce differentiation of

Accepted December 31, 1996

Project supported by the National Natural Science Foundation of China, No. 39320003. human promyelocytic leukemia HL-60 cells.<sup>3</sup> However, the mechanism of its antitumor activity was still unclear. In this work, we further investigated the tumor-inhibitory effect of ANO to explore the possible mechanisms of its action.

## **MATERIALS AND METHODS**

## Drug

ANO was produced by Shanghai No. 19 Pharmaceutical Factory and purified in our institute.<sup>4</sup> Its stock solution was made in ethanol at the concentration of 50 mM. The final concentration of ethanol was less than 0.1% which had no significant effect on the parameters measured in the present experiments.

# **Cell Culture**

Human leukemia HL-60 and K562 cells were maintained in RPMI 1640 medium (Gibco BRL) supplemented with 10% heat-inactivated calf serum, 100 IU/ml penicillin, 100  $\mu$ g/ml streptomycin at 37 °C in a humidified atmosphere containing 95% air/5% CO<sub>2</sub>. Exponentially growing cells were used in all experiments.

## **Morphological Examination**

Cell morphological changes were observed

under electron microscope.

#### **DNA Gel Electrophoresis**

Analysis of DNA fragmentation was performed by agarose gel electrophoresis according to the method described by Kamesaki, et al.<sup>5</sup>

#### **Cell Cycle Analysis**

The cells untreated and treated were harvested by centrifugation, washed in PBS, and fixed in icecold 70% ethanol overnight. Following fixation, the cells were centrifugated and the cellular DNA was stained with 50  $\mu$ g/ml propidium iodide (Sigma) dissolved in PBS containing RNase A 20  $\mu$ g/ml (Boehringer Mannheim), 0.1% Triton X-100 (Sigma). The fluorescence of individual cells was measured by FACStar plus flow cytometer (Becton Dickinson).

#### RESULTS

# **Cell Growth**

The dose-response effect of ANO on the growth of human leukemia HL-60 and K562 cells was examined. Exposure of these two cell lines to ANO  $2.5-50 \mu$ M for 48 h resulted in dose- and timedependent growth inhibition (Figure 1). HL-60 cells were more sensitive to ANO than K562 cells as reflected by the IC50 value (26  $\mu$ M for HL-60 cells and 38  $\mu$ M for K562 cells).

#### **Morphological Assessment**

Electron microscopic observation showed that ANO-treated HL-60 cells exhibited cell shrinkage, chromatin condensation, and nuclear fragmentation, characteristic of apoptosis (Figure 2). K562 cells had the same morphological changes as that in HL-60 cells.

## **DNA Gel Electrophoresis**

Agarose gel electrophoresis of DNA extracted from ANO-treated cells revealed typical "ladder" pattern in agarose gel, suggesting that DNA fragmentation preferentially occur at internucleosomal or linker DNA regions which was a major hallmark for apoptosis (Figure 3, 4). DNA electrophoresis also

2

showed that ANO-induced apoptosis of K562 cells was not prevented by protein synthesis inhibitor cycloheximide (CHX) (Figure 3) and RNA synthesis inhibitor actinomycin D (Act D) (data not shown), in contrast, these two agents enhanced the extent of apoptosis. Interestingly, HL-60 cell apoptosis in the presence of ANO was partially blocked by CHX and Act D. The blocking effect of CHX was stronger than that of Act D (Figure 4).



Fig. 1. Effect of  $\alpha$ -anordrin (ANO) on the growth of K562 (A) and HL-60 cells (B). Cells were incubated with ANO 2.5-50  $\mu$ M for 24-48 h. n=3,  $\overline{x\pm s}$ . 'P<0.05, "P<0.01 vs control.

## **Cell Cycle Analysis**

It has been widely accepted that apoptotic cells have reduced DNA stainability following staining with a variety of fluorochromes. So, the appearance of cells with low stainability, lower than that of  $G_1$  cells ("sub- $G_1$  peak") in cultures has been considered to be the marker of apoptosis.<sup>6</sup> ANO treatment led to the formation of "sub- $G_1$  peak" in DNA content frequency distribution histogram (Figure 5) and caused approximately 50–60% cell apoptosis after exposure of HL-60 or K562 cells to 50  $\mu$ M ANO for 48 h. Apoptosisinducing effect was dose- and time-dependent.



Fig. 2. Morphology of HL-60 cells. Cells were untreated (A) and treated with  $\alpha$ -anordrin 50 µmol L-1 for 48 h (B, C, D). Arrow: A, normal HL-60 cells; B, apoptotic cells; C, apoptotic body; D, necrotic cells. (Electron micrograph, original magnification: A, B, C,  $\times$  3100; D,  $\times$ 4700; Bar=5 µm.



Fig. 3. Agarose gel electrophoresis of DNA extracted from K562 cells, untreated (lane 1) or treated with cycloheximide (CHX) 1  $\mu$ M (lane 2),  $\alpha$ -anordrin (ANO) 50  $\mu$ M (lane 3), ANO 50  $\mu$ M+CHX 1  $\mu$ M (lane 4), CHX 400  $\mu$ M (lane 5) for 24 h, respectively. M: molecular weight marker.

ANO possessed antiestrogenic activity which was related to its contraceptive action.<sup>7</sup> In this work, we investigated whether or not the apoptosis-inducing effect of ANO could be antagonized by estradiol ( $E_2$ ) and potentiated by estrogen receptor (ER) antagonist

tamoxifen (TAM). As expected, TAM synergestically augmented and  $E_2$  partially suppressed apoptosis caused by ANO, which was analyzed by median-effect principle software provided by Prof. Chou.<sup>8</sup> In addition, both TAM and  $E_2$  could induce HL-60 cell apoptosis, altered cell cycle distribution (Figure 5).



Fig. 4. Agarose gel electrophoresis of DNA extracted from HL-60 cells. HL-60 cells were untreated (lane 1) or treated with  $\alpha$ -anordrin (ANO) 50  $\mu$ M (lane 2), cycloheximide (CHX) 1  $\mu$ M (lane 3), ANO 50  $\mu$ M+CHX 1  $\mu$ M (lane 4), actinocycin D (Act D) 0.005  $\mu$ M (lane 5), and ANO 50  $\mu$ M+Act D 0.005  $\mu$ M (lane 6) for 24 h. M:molecular weight marker.

#### DISCUSSION

Antineoplastic agents exert their antitumor activity by different mechanisms including growth inhibition, differentiation-induction, immune response modification, and recently defined mechanism: induction of apoptosis of tumor cells. Among them, apoptosis is one of the most attractive area of cancer research in recent years. Evidence accumulated demonstrated that the antitumor potency of virous antitumor drugs was closely associated with their ability to induce target cell apoptosis.9 So, investigation of the characteristics of a drug in triggering apoptosis will provide important information for cancer chemotherapy. The results obtained in the present study clearly showed that ANO could induce apoptosis in both HL-60 and K562 cells which was confirmed by the appearance of the internucleosomal DNA fragmentation and typical apopotic morphological changes after treatment with ANO.

Apoptosis is a tightly controlled gene-directed process, during which a number of related genes express their product to initiate the cell death program.<sup>10</sup> Thus, apoptosis occurring in a number of circumstances could be abrogated or delayed by

inhibitors of macromolecular synthesis.<sup>11,12</sup> Indeed, CHX and Act D did diminish the extent of apoptosis induced by ANO in HL-60 cells, but in K562 cells, it was not observed. Even CHX and Act D enhanced ANO-induced apoptosis. These data suggested that diverse regulatory mechanisms of apoptosis exist in different cell lines.



Fig. 5. Effect of  $\alpha$ -anordrin (ANO), tamoxifen (TAM), estradiol (E2) each alone or in combinaton on apoptosis and the cell cycle distribution of HL-60 cells. Cells were treated with respective drug for 8 h. A: control, G<sub>1</sub>=35%, S=51%, G<sub>2</sub>/M=14%, Ap=4%; B: TAM 10  $\mu$ M, G<sub>1</sub>=42%, S=46%, G<sub>2</sub>/M=12%, Ap=26%; C: E2 10  $\mu$ M, G<sub>1</sub>=9%, S=38%, G<sub>2</sub>/M=53%, Ap=17%; D: ANO 25  $\mu$ m, G<sub>1</sub>=52%, S=44%, G<sub>2</sub>/M=4%, Ap=20%; E: ano 25  $\mu$ m+tam 10  $\mu$ m, G<sub>1</sub>=38%, S=58%, G<sub>2</sub>/M=4%, Ap=58%; F: ano 25  $\mu$ m+e2 10  $\mu$ m G<sub>1</sub>=38%, S=44%, G<sub>2</sub>/M=18%, Ap=21%, respectively.

ANO-induced apoptosis was substantially enhanced by ER antagonist TAM and partially abolished by ER agonist E2, it is indicated that ER played an important role in mediating this effect. But the fact that E<sub>2</sub> was unable to abrogated the apoptosis completely implied that other pathways might be involved in this process. Sutherland et al.<sup>13-15</sup> have reported that E<sub>2</sub> could not reverse the rapid cytotoxic effect of high concentration TAM and identified a high affinity antiestrogen binding site different from the classic ER. Considering the antiestrogenic activity of ANO, it appears to be likely that ANO exerts its cytotoxicity also in part through its interaction with the antiestrogen binding site.

#### REFERENCES

- Weng SM, Xu YP, Xu B. Antitumor effect of alpha isomer of anordrin *in vitro* and cell cycle arrest at G<sub>1</sub> phase. Acta Pharmacol Sin 1994; 15:47.
- 胥彬,周佩琴,俞伟娟. 双炔失碳酯的抗实验肿瘤 作用研究. 肿瘤(上海) 1989; 9:197.
- 胥彬,顾健,常美平,等. α-双炔失碳酯对 HL-60 细胞诱导分化的研究. 中国癌症杂志 1994; 4:36.
- 刘淑卿,朱大元,高清勇,等. 双炔失碳酯差向异 构体的分离和定量分析. 生殖和避孕 1987;7:36.
- Kamesaki S, Kamesaki H, Jorgensen TJ, et al. bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-

induced DNA strand breaks and repair. Cancer Res 1993; 53:4251.

- Darzynkiewics Z, Bruno S, Del Bino G, et al. Features of apoptosis cells measured by flow cytometry. Cytometry 1992; 13:795.
- 7. Mehta RR, Jenco JM, Chatterton RT. Antiestrogenic and antifertility actions of anordrin  $(2\alpha, 17\alpha$ diethynyl-A-nor-5 $\alpha$ -androstance-2 $\beta$ , 17 $\beta$ -diol 2, 17dipropionate). Steroids 1981; 38:679.
- Chou TC. The median-effect principle and the combination index for quantitation of synergism and antagonism. In synergism and antagonism in chemotherapy (Chou TC, and Rideout D Eds.) PP. 3-60, Academic Press, San Diego. 1991.
- 楼丽广,胥彬. 抗肿瘤药物与细胞程序死亡. 中 国肿瘤临床 1995; 22:136.
- 楼丽广,胥彬. 编程性细胞死亡与癌基因. 中国 癌症杂志 1995; 5:123.
- 11. Evans DL, Dive C. Effects of cisplatin on the

induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes. Cancer Res 1993; 53:2133.

- Ling YH, Priebe W, Perez-Soler R. Apoptosis induced by anthracycline antibiotics in p388 parent and multidrug-resistant cells. Cancer Res 1993; 53:1845.
- Sutherland RL, Hall RE, Taylor IW. Cell proliferation kinetics of MCF<sub>7</sub> human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res 1983; 43:3998.
- Bardon S, Vignon F, Derocq D, et al. The antiproliferative effect of tamoxifen in breast cancer cells: role of the estrogen receptor. Mol Cell Endocrinol 1984; 35:89.
- Sutherland RL, Murphy LC, Foo MS, et al. High affinity antiestrogen binding site distinct from the estrogen receptor. Nature (Lond) 1980; 288:273.